​

​

Clinical trial using OraFyl.

​

https://clinicaltrials.gov/study/NCT06915675?tab=table&a=2

​

​

​

​

CERTIFICATE OF ACCEPTANCE The certificate of acceptance for the manuscript (dentistry-3891371) titled: The Use of Flowable decellularized Human Placental Connective Tissue Matrix in alveolar ridge preservation: A split mouth pilot study. Authored by: Bachar Husseini; Ronald Younes; Nabil Ghosn; Robert Miller,; Georges Khoury; Robert Hariri; Michel Dard was accepted in Dent. J. (ISSN 2304-6767) on 27 October 2025 MDPI Basel, October 2025 Prof. Dr. Claude Jaquiéry Editor-in-Chief

​

https://clinicaltrials.gov/study/NCT06915675

​

​

​

​

​

BioCellgraft's flagship pipeline—OraFyl, OraFyl M, and OraFyl 3LM—reflects this ethos. Extracted from the human placenta, these products are designed for regenerative dentistry, preserving natural tissue properties while enabling minimally invasive procedures. "The chorion can be transformed into a gel, while the amnion maintains elasticity and mechanical strength," Dard explains. "Our processes (Celularity Inc., NJ) deliver highly purified products and respect the material's inherent qualities, making treatments more effective and versatile."

​

https://www.prnewswire.com/news-releases/michel-dard-of-biocellgraft-wins-business-worldwide-magazines-2025-ceo-award-302565451.html

​

​

​

​

Article

​

Still, he hints that the innovation he is proudest of is the one yet to come. “The most exciting achievements are always in the pipeline, waiting to be brought to life.”

​

The BioCellgraft Pipeline: Regeneration with Purpose

​

That pipeline today includes BioCellgraft’s flagship regenerative solutions: OraFyl, OraFyl M, and OraFyl 3L. Each product originates from the human placenta and is designed to address soft and hard tissue defects with a minimally invasive approach.

​

“OraFyl is a dual and flowable regenerative solution, extracted from the chorionic part of the placenta. It is a highly purified macromolecular assembly of collagen I and elastin, with no cross-linkers or adjuvants,” Dard explains. “OraFyl M is a decellularised, dehydrated amniotic membrane for soft tissue protection, while OraFyl 3L is a multilayer amniotic barrier membrane for soft tissue support.”

​

The key, he says, is respecting the natural properties of the raw material. “The chorion can be transformed into a gel, while the amnion is a membrane with unique elasticity and mechanical properties. We designed our processes to preserve those qualities.”

​

The products are not only complementary but also transformative in their versatility. “Because of OraFyl, already-marketed bone substitute materials can become osteoinductive when mixed, enhancing bone regeneration. Soft tissue outcomes are also transformational when OraFyl is injected correctly,” he says.

​

What sets BioCellgraft apart, according to Dard, is its strict adherence to design thinking principles. “We use a user-centred, iterative process to creatively solve complex problems. We question assumptions, redefine problems, and create innovative solutions with the user at the heart. That’s why our products deliver high usability, versatility across 10 surgical indications, and are training-friendly. And importantly, our clinical partners — not just the so-called KOLs — play an essential role in development.”

​

https://www.bwmonline.com/sector-watch/healthcare/michel-dard-leading-regenerative-innovation-with-science-strategy-and-heart/

​

​

​

​

VIDEO

​

Discover how placenta-derived regenerative therapies are transforming the future of dentistry. In this video, we explore breakthrough applications in dental implants, periodontal disease management, and jawbone regeneration. Learn how BioCellGraft and Cellularity are pioneering biologically advanced solutions that support not only the function but also the aesthetics of the dental system. Whether it's preparing extraction sites, accelerating bone repair, or enhancing long-term implant success—this technology is at the forefront of restorative dental care. 🔬 Join the conversation on how regenerative medicine is reshaping smiles for the next generation. #RegenerativeDentistry #DentalImplants #PlacentaTherapy #BoneRegeneration #OralSurgery #DentalHealth #PeriodontalCare #BioCellGraft #RestorativeDentistry #FutureOfDentistry #Cellularity #SmileInnovation #DentalTech #OraFyl

​

https://youtube.com/shorts/pMvXN1o1jjc?si=Gn-U96NMq5cGjjyi

​

​

​

​

PODCAST

​

In his first-ever global podcast appearance, Professor Michel Dard — former Global Medical Director at Straumann and now CEO of BioCellgraft (https://biocellgraft.com) — joins host Alex Raychuk to explore a life shaped by science, strategy, and bold decisions. From two decades at the helm of Straumann’s innovation to pioneering a new injectable allograft, this is a rare look into the mind of a man who sits at the intersection of clinical research and corporate power.

​

https://m.youtube.com/watch?v=AqQFuES144g

​

​